Toshihiko Kuroda

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 66:10127-35. 2006
  2. ncbi Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors
    Ta-Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:6791-9. 2006
  3. ncbi Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
    Ta-Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, CPZN-3800 Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    Mol Ther 14:789-97. 2006
  4. ncbi Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    BMC Biotechnol 6:40. 2006
  5. ncbi Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
  6. ncbi Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors
    Kaoru Tamura
    Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Mol Ther 21:68-77. 2013
  7. ncbi Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
    Hiroshi Fukuhara
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA
    Cancer Res 65:10663-8. 2005
  8. ncbi Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction
    Deva S Jeyaretna
    Massachusetts General Hospital, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Boston, MA 02114, USA
    Curr Opin Mol Ther 9:447-66. 2007

Collaborators

Detail Information

Publications8

  1. ncbi Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 66:10127-35. 2006
    ..Our results suggest that a transcriptionally regulated oncolytic herpes vector targeting beta-catenin/Tcf signal is very efficacious against CRC tumors carrying an APC gene mutation between the first and second 20-amino-acid repeats...
  2. ncbi Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors
    Ta-Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:6791-9. 2006
    ..This strategy can be applied to other oncolytic viruses and for clinical translation...
  3. ncbi Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
    Ta-Chiang Liu
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, CPZN-3800 Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    Mol Ther 14:789-97. 2006
    ..Enhancing the antiangiogenic properties of oncolytic HSV through the expression of antiangiogenic factors such as PF4 is a powerful new strategy that targets both the tumor cells and tumor vasculature...
  4. ncbi Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases
    Toshihiko Kuroda
    Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    BMC Biotechnol 6:40. 2006
    ..coli. Thus, we sought a method to generate recombinant oncolytic HSV vectors more easily and quickly using BAC technology...
  5. ncbi Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
    ..This is important for designing new oHSV vectors and clinical trials. Moreover, the new glioma models described in this study provide powerful tools for testing experimental therapeutics and studying invasion and angiogenesis...
  6. ncbi Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors
    Kaoru Tamura
    Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Mol Ther 21:68-77. 2013
    ..This study sheds new light on the mechanism by which oHSV and TRAIL function in concert to overcome therapeutic-resistance, and provides an oncolytic virus based platform to target a broad spectrum of different cancer types...
  7. ncbi Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
    Hiroshi Fukuhara
    Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA
    Cancer Res 65:10663-8. 2005
    ..The results show that "arming" with multiple transgenes can improve the efficacy of oncolytic HSV-1 vectors. The use of our system may facilitate the development and testing of various armed oncolytic HSV-1 vectors...
  8. ncbi Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction
    Deva S Jeyaretna
    Massachusetts General Hospital, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Boston, MA 02114, USA
    Curr Opin Mol Ther 9:447-66. 2007
    ..This review discusses the current state of research into the development of oncolytic HSV-1 vectors, and highlights the promise that armed oncolytic HSV-1 vectors might hold for the future...